AAV
Beyond's analysis on AAV
Recent news mentioning AAV
- — Aave Nears $1B Milestone for V4 Deposits
- — EpilepsyGTx et Viralgen collaborent pour faire progresser le programme de thérapie génique à base d'AAV contre l'épilepsie, en vue d'un premier essai clinique chez l'humain
- — EpilepsyGTx y Viralgen impulsan un programa de terapia génica con vectores AAV para la epilepsia
- — EpilepsyGTx und Viralgen arbeiten gemeinsam daran, das AAV-Gentherapieprogramm zur Behandlung von Epilepsie im Vorfeld der ersten klinischen Studie am Menschen voranzutreiben
- — EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial
- — SAAVI ENERGÍA ANNOUNCES THE CLOSING OF THE MERGER TRANSACTION WITH GRUPO MÉXICO, S.A.B DE C.V.
- — Strengthen Total AAV Potency Assurance with NGS Sequence Analysis, Upcoming Webinar Hosted by Xtalks
- — FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- — $230B Fixed-Income Giant Enters Aave Collateral Debate With Tokenized Fund
- — Andelyn Biosciences to Implement Curator® Platform to Develop and Manufacture Gene Therapy AAV9-GM2 for Queen's University to Treat GM2 Gangliosidoses
- — Irán responde a Trump: Ormuz no se puede conquistar "con un tuit ni con portaaviones"
- — AAVE Price Forecast: Can This DEX Token Deliver 300% Gains Next?